< Back to search
Filter
1
Active & Responsive

UWCCC Molecular Tumor Board Registry

for
Hematologic Neoplasms, Solid Neoplasm
Location: Madison WI
Sponsor: University of Wisconsin, Madison

Sex: All

Age: 18+

Code: NCT03023202

Recruiting
Active & Responsive

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer

for
Localized Renal Pelvis and Ureter Urothelial Carcinoma,
Location: Seattle WA
Sponsor: University of Washington

Sex: Male

Age: 18+

Code: NCT01050504

Recruiting
Active & Responsive

Ambient Sensing Room to Detect Early Signs of Adverse Events in Hospitalized Patients With Cancer

for
Hematopoietic and Lymphatic System Neoplasm,
Location: Rochester MN
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT07477886

Recruiting
Active & Responsive

Evaluation of Early Identification of Cognitive Side Effects of Immunotherapy

for
Hematopoietic and Lymphatic System Neoplasm,
Location: Minneapolis MN
Sponsor: Masonic Cancer Center, University of Minnesota

Sex: All

Age: 18+

Code: NCT06414278

Recruiting
Active & Responsive

CREATE: Art for Children With Cancer

for
Hematopoietic and Lymphatic System Neoplasm,
Location: Portland OR
Sponsor: OHSU Knight Cancer Institute

Sex: All

Age: 8 - 13

Code: NCT06342453

Recruiting

Interested in new solid tumor trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image
Active & Responsive

Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors

for
Advanced Malignant Solid Neoplasm,
Location: Portland OR
Sponsor: OHSU Knight Cancer Institute

Sex: All

Age: 18+

Code: NCT06320405

Phase1, Phase2, Recruiting
Active & Responsive

Biomarkers to Predict Cancer Therapy-related Cardiotoxicity

for
Hematopoietic and Lymphatic System Neoplasm,
Location: Jacksonville FL, Tampa FL, Scottsdale AZ
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT06353191

Recruiting
Active & Responsive

A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors

for
Neuroblastoma, Sarcoma
Location: The Bronx NY, Washington D.C. DC, Columbus OH,
Sponsor: Nationwide Children's Hospital

Sex: All

Age: 1 - 40

Code: NCT05135975

Phase2, Recruiting
Active & Responsive

A Phase 1/2 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors

for
Metastatic Hepatocellular Carcinoma,
Location: New York NY, Pittsburgh PA, Birmingham AL, Nashville TN,
Sponsor: BeOne Medicines

Sex: All

Age: 18+

Code: NCT06427941

Phase1, Phase2, Recruiting
Active & Responsive

Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors

for
Neuroblastoma, Sarcoma, Osteosarcoma
Location: Palo Alto CA
Sponsor: Stanford University

Sex: All

Age: 2 - 30

Code: NCT06500819

Phase1, Recruiting
Active & Responsive

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

for
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia,
Location: Madison WI
Sponsor: University of Wisconsin, Madison

Sex: All

Age: 0 - 21

Code: NCT02508038

Phase1, Recruiting
Active & Responsive

Improving Care for Rural Patients With Solid Tumors

for
Lung Cancer, Head and Neck Cancer, Thyroid Cancer,
Location: Greeley CO, Aurora CO, Loveland CO, Fort Collins CO,
Sponsor: University of Colorado, Denver

Sex: All

Age: 18 - 70+

Code: NCT04916990

Recruiting
Active & Responsive

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

for
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC),
Location: New York NY, East Brunswick NJ, Philadelphia PA,
Sponsor: IDEAYA Biosciences

Sex: All

Age: 18+

Code: NCT07277413

Phase1, Recruiting
Active & Responsive

A Phase 1 and 2 Study of VMD-102 in Hepatocellular Carcinoma and Other Solid Tumors

for
Hepatocellular Carcinoma (HCC), Metastatic Uveal Melanoma,
Location: Scottsdale AZ
Sponsor: VM Discovery, Inc.

Sex: All

Age: 18 - 70+

Code: NCT07636785

Phase1, Phase2, Recruiting
Active & Responsive

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

for
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy),
Location: Stony Brook NY, New York NY, Montreal, Baltimore MD,
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT06535607

Phase2, Recruiting
Active & Responsive

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

for
Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic,
Location: Hackensack NJ, Fairfax VA, Buffalo NY, Cleveland OH,
Sponsor: Whitehawk Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT07444814

Phase1, Recruiting
Active & Responsive

A Study of DM005 in Patients With Advanced Solid Tumors

for
Carcinoma, Non-Small-Cell Lung,
Location: Fairfax VA, Detroit MI, Dallas TX
Sponsor: Doma Biopharmaceutical（Suzhou）Co., Ltd.

Sex: All

Age: 18+

Code: NCT06515990

Phase1, Phase2, Recruiting
Active & Responsive

IKS014 in Advanced Solid Tumors That Express HER2

for
Breast Cancer, Gastric Cancer, Gastroesophageal-junction Cancer
Location: Boston MA, Nashville TN, Fort Worth TX,
Sponsor: Iksuda Therapeutics Ltd.

Sex: All

Age: 18+

Code: NCT05872295

Phase1, Recruiting
Active & Responsive

177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors

for
Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer,
Location: Dothan AL, Grand Rapids MI, Omaha NE
Sponsor: Radiopharm Theranostics, Ltd

Sex: All

Age: 18+

Code: NCT07189871

Phase1, Phase2, Recruiting
Active & Responsive

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

for
Malignant Neoplasm
Location: Quebec, New Brunswick NJ, Montreal, Fairfax VA, Toronto,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07247110

Phase1, Recruiting